Other studies have evaluated lipoprotein using AST and ALT as surrogate markers of hepatic dysfunction, but these enzymes are normal in up to 78% of patients with NAFLD and thus cannot be used to accurately diagnose the disease or distinguish steatosis from NASH [20–22]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.